2199 related articles for article (PubMed ID: 7522964)
1. Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody.
Chapman PB; Gillies SD; Houghton AN; Reilly RM
Cancer Immunol Immunother; 1994 Sep; 39(3):198-204. PubMed ID: 7522964
[TBL] [Abstract][Full Text] [Related]
2. Light chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship among avidity, effector functions, tumor targeting, and antitumor activity.
Chapman PB; Lonberg M; Houghton AN
Cancer Res; 1990 Mar; 50(5):1503-9. PubMed ID: 2105840
[TBL] [Abstract][Full Text] [Related]
3. Homophilic binding of mouse monoclonal antibodies against GD3 ganglioside.
Chapman PB; Yuasa H; Houghton AN
J Immunol; 1990 Aug; 145(3):891-8. PubMed ID: 1695649
[TBL] [Abstract][Full Text] [Related]
4. Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells.
Welt S; Carswell EA; Vogel CW; Oettgen HF; Old LJ
Clin Immunol Immunopathol; 1987 Nov; 45(2):214-29. PubMed ID: 3665201
[TBL] [Abstract][Full Text] [Related]
5. The role of homophilic binding in anti-tumor antibody R24 recognition of molecular surfaces. Demonstration of an intermolecular beta-sheet interaction between vh domains.
Kaminski MJ; MacKenzie CR; Mooibroek MJ; Dahms TE; Hirama T; Houghton AN; Chapman PB; Evans SV
J Biol Chem; 1999 Feb; 274(9):5597-604. PubMed ID: 10026176
[TBL] [Abstract][Full Text] [Related]
6. The idiotype (Id) cascade in mice elicited the production of anti-R24 Id and anti-anti-Id monoclonal antibodies with antitumor and protective activity against human melanoma.
Ramos AS; Parise CB; Travassos LR; Han SW; de Campos-Lima PO; de Moraes JZ
Cancer Sci; 2011 Jan; 102(1):64-70. PubMed ID: 21070480
[TBL] [Abstract][Full Text] [Related]
7. Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicity.
Triozzi PL; Shah JJ; Wang WQ; Aldrich W; Edberg JC; Su K; Carlisle R; Conry R; LoBuglio AF; Forero A
Cancer Biother Radiopharm; 2006 Dec; 21(6):553-60. PubMed ID: 17257070
[TBL] [Abstract][Full Text] [Related]
8. Characterization of an Ig VH idiotope that results in specific homophilic binding and increased avidity for antigen.
Yan X; Evans SV; Kaminki MJ; Gillies SD; Reisfeld RA; Houghton AN; Chapman PB
J Immunol; 1996 Aug; 157(4):1582-8. PubMed ID: 8759742
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of a novel monoclonal antibody with high binding affinity to ganglioside GD3.
Ohta S; Honda A; Tokutake Y; Yoshida H; Hanai N
Cancer Immunol Immunother; 1993; 36(4):260-6. PubMed ID: 8439988
[TBL] [Abstract][Full Text] [Related]
10. Recombinant antibodies against ganglioside expressed on tumor cells.
Hanai N; Nakamura K; Shitara K
Cancer Chemother Pharmacol; 2000; 46 Suppl():S13-7. PubMed ID: 10950141
[TBL] [Abstract][Full Text] [Related]
11. Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside.
Nasi ML; Meyers M; Livingston PO; Houghton AN; Chapman PB
Melanoma Res; 1997 Aug; 7 Suppl 2():S155-62. PubMed ID: 9578432
[TBL] [Abstract][Full Text] [Related]
12. Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma.
Bajorin DF; Chapman PB; Wong GY; Cody BV; Cordon-Cardo C; Dantes L; Templeton MA; Scheinberg D; Oettgen HF; Houghton AN
Melanoma Res; 1992 Dec; 2(5-6):355-62. PubMed ID: 1292783
[TBL] [Abstract][Full Text] [Related]
13. GD3 ganglioside antibody augments tumoricidal capacity of canine blood mononuclear cells by induction of interleukin 12.
Helfand SC; Dickerson EB; Munson KL; Padilla ML
Cancer Res; 1999 Jul; 59(13):3119-27. PubMed ID: 10397254
[TBL] [Abstract][Full Text] [Related]
14. Anti-GD3 monoclonal antibody analysis of childhood T-cell acute lymphoblastic leukemia: detection of a target antigen for antibody-mediated cytolysis.
Reaman GH; Taylor BJ; Merritt WD
Cancer Res; 1990 Jan; 50(1):202-5. PubMed ID: 2403416
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites.
Vadhan-Raj S; Cordon-Cardo C; Carswell E; Mintzer D; Dantis L; Duteau C; Templeton MA; Oettgen HF; Old LJ; Houghton AN
J Clin Oncol; 1988 Oct; 6(10):1636-48. PubMed ID: 3171629
[TBL] [Abstract][Full Text] [Related]
16. Potential to involve multiple effector cells with human recombinant interleukin-2 and antiganglioside monoclonal antibodies in a canine malignant melanoma immunotherapy model.
Helfand SC; Soergel SA; Donner RL; Gan J; Hank JA; Lindstrom MJ; Sondel PM
J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):188-97. PubMed ID: 7834118
[TBL] [Abstract][Full Text] [Related]
17. A mouse/human chimeric anti-(ganglioside GD3) antibody with enhanced antitumor activities.
Shitara K; Kuwana Y; Nakamura K; Tokutake Y; Ohta S; Miyaji H; Hasegawa M; Hanai N
Cancer Immunol Immunother; 1993 Jun; 36(6):373-80. PubMed ID: 8500110
[TBL] [Abstract][Full Text] [Related]
18. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.
Harel W; Shau H; Hadley CG; Morgan AC; Reisfeld RA; Cheresh DA; Mitchell MS
Cancer Res; 1990 Oct; 50(19):6311-5. PubMed ID: 2400994
[TBL] [Abstract][Full Text] [Related]
19. R24 anti-GD3 ganglioside antibody can induce costimulation and prevent the induction of alloantigen-specific T cell clonal anergy.
Boussiotis VA; Pardo NA; Collins H; Houghton A; Ritz J; Nadler LM; Soiffer RJ
Eur J Immunol; 1996 Sep; 26(9):2149-54. PubMed ID: 8814260
[TBL] [Abstract][Full Text] [Related]
20. Construction of humanized anti-ganglioside monoclonal antibodies with potent immune effector functions.
Nakamura K; Tanaka Y; Shitara K; Hanai N
Cancer Immunol Immunother; 2001 Jul; 50(5):275-84. PubMed ID: 11499811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
